EyePoint Pharmaceuticals - EYPT Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYPT shares.
View EYPT analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year target prices for EyePoint Pharmaceuticals' shares. Their EYPT share price forecasts range from $21.00 to $35.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 275.0% from the stock's current price.
View analysts price targets for EYPT or view top-rated stocks among Wall Street analysts.

EyePoint Pharmaceuticals' stock was trading at $12.24 at the start of the year. Since then, EYPT shares have decreased by 41.2% and is now trading at $7.20.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EYPT earnings forecast.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.11. The business earned $9.06 million during the quarter, compared to the consensus estimate of $9.60 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 50.36% and a negative net margin of 186.14%. During the same period in the prior year, the business earned ($0.30) EPS.

EyePoint Pharmaceuticals's stock reverse split on the morning of Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

EyePoint Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (16.00%), Point72 Asset Management L.P. (3.58%), Goldman Sachs Group Inc. (2.61%), Verition Fund Management LLC (1.58%), State Street Corp (1.19%) and Millennium Management LLC (1.01%). Insiders that own company stock include George Elston and Nancy Lurker.
View institutional ownership trends.

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYPT stock can currently be purchased for approximately $7.20.

EyePoint Pharmaceuticals (NASDAQ:EYPT) has a market capitalization of $245.30 million and generates $35.31 million in revenue each year. The company earns $-58,420,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

The company employs 122 workers across the globe.

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The official website for the company is eyepointpharma.com. The company can be reached via phone at (617) 926-5000, via email at eyepoint@argotpartners.com, or via fax at 617-926-5050.